Evidence map›Paper›PMID 38940870›Full record

ArticleAnalytical and bioanalytical chemistry2024

Cohort-based strategies as an in-house tool to evaluate and improve phenotyping robustness of LC-MS/MS lipidomics platforms.

Benedikt Zöhrer, Cristina Gómez, Joaquim Jaumot, Helena Idborg, Signe S Torekov, Åsa M Wheelock, Craig E Wheelock, Antonio Checa

Abstract read
In one paragraph

Article in Analytical and bioanalytical chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Benedikt ZöhrerRespiratory Medicine Unit, Department of Medicine Solna, Center for Molecular Medicine, Karolinska Institutet, 171 76, Stockholm, Sweden.
Cristina GómezUnit of Integrative Metabolomics, Institute of Environmental Medicine, Karolinska Institute, 171 65, Solna, Sweden.
Joaquim JaumotDepartment of Environmental Chemistry, IDAEA-CSIC, Jordi Girona 18-26, E08034, Barcelona, Spain.
Helena IdborgDivision of Rheumatology, Department of Medicine, Karolinska Institutet and Karolinska University Hospital, Solna, Stockholm, Sweden.
Signe S TorekovDepartment of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
Åsa M WheelockRespiratory Medicine Unit, Department of Medicine Solna, Center for Molecular Medicine, Karolinska Institutet, 171 76, Stockholm, Sweden.
Craig E WheelockDepartment of Respiratory Medicine and Allergy, Karolinska University Hospital, 171 76, Stockholm, Sweden.
Antonio ChecaUnit of Integrative Metabolomics, Institute of Environmental Medicine, Karolinska Institute, 171 65, Solna, Sweden. antonio.checa@ki.se.ORCID http://orcid.org/0000-0002-0674-3329

Funding

H2020 ITN Arthritis Heal 812890Hjärt-Lungfonden HLF 20190017Hjärt-Lungfonden HLF 20210519Hjärt-Lungfonden HLF 20230363Hjärt-Lungfonden HLF 20230463Ministerio de Ciencia e Innovación MCIU/AEI/10.13039/501100011033Severo Ochoa Excelencia CEX2018-000794-SStiftelsen Konung Gustaf V:s 80-årsfond FAI-2020-0732Vetenskapsrådet 2018-00520Vetenskapsrådet 2022-00796
6 · The paper itself

Abstract

In recent years, instrumental improvements have enabled the spread of mass spectrometry-based lipidomics platforms in biomedical research. In mass spectrometry, the reliability of generated data varies for each compound, contingent on, among other factors, the availability of labeled internal standards. It is challenging to evaluate the data for lipids without specific labeled internal standards, especially when dozens to hundreds of lipids are measured simultaneously. Thus, evaluation of the performance of these platforms at the individual lipid level in interlaboratory studies is generally not feasible in a time-effective manner. Herein, using a focused subset of sphingolipids, we present an in-house validation methodology for individual lipid reliability assessment, tailored to the statistical analysis to be applied. Moreover, this approach enables the evaluation of various methodological aspects, including discerning coelutions sharing identical selected reaction monitoring transitions, pinpointing optimal labeled internal standards and their concentrations, and evaluating different extraction techniques. While the full validation according to analytical guidelines for all lipids included in a lipidomics method is currently not possible, this process shows areas to focus on for subsequent method development iterations as well as the robustness of data generated across diverse methodologies.

Indexed as

LipidomicsTandem Mass SpectrometryChromatography, LiquidHumansLipidsLiquid Chromatography-Mass SpectrometryPhenotypeReference StandardsReproducibility of ResultsSphingolipidsLipidsSphingolipidsBioanalytical methodsLC-MS/MSLipidomicsSphingolipids

Identifiers

PMID38940870
PMCPMC11427549

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.